Objective: We hypothesized that most patients with 22q11.2 deletion and a history of hypocalcemia have inadequate parathyroid function, manifested by intact parathyroid hormone levels below normal.

Günther et al. investigated parathyroid function using knockout mice that are deficient in the transcription factor Gcm2 (ref. 1). Gcm2 stands for “glial cells missing-2” because disruption ...

Scarless transoral thyroidectomy or transoral vestibular approach (TOVA) allows for the safe and total removal of the thyroid or parathyroid glands with absolutely no external scarring to the neck. Of ...

Topline data were announced from a phase 3 trial evaluating eneboparatide in adults with chronic hypoparathyroidism.

UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...

The film explores the role of endocrine glands in various bodily functions such as nutrition, growth, and reproduction. It demonstrates experiments conducted on a goat to study the effects of removing ...

Hypoparathyroidism means your body doesn't have enough parathyroid hormone (PTH). PTH is made in your parathyroid glands, four pea-sized lobes in your neck. PTH controls calcium, so you'll ...

The Thyroid & Parathyroid Center at Baylor Medicine is a world-class medical facility in Houston, TX, where patients can be seen simultaneously by a surgeon and endocrinologist for treatment of both ...

Septerna Inc. has announced its decision to discontinue a healthy volunteer phase I trial of SEP-786, an oral small-molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for ...

LONDON, UK I March 17, 2025 I High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary ...